Custom organoid screening models
Client-selected organoids screened with or without allogeneic MHC-matched PBMCs, tailored to your research needs. A variety of compound classes can be screened ranging from small molecules to biologics, viral vectors, cell engagers, and cellular therapies.

​

• Tumor Origin: Pan-Cancer, client-selected indications

• Molecular Profiling: Client-selected molecular alterations, mutations, CNVs, fusions, etc.
   

Predefined organoid screening models
Predefined models for routine screening in organoids containing actionable alterations across cancer types. Compounds can be screened alone and in combinations, providing a rapid and cost-effective alternative to in vivo preclinical animal experiments.

​

• PanTumor 60™: primary and metastatic tumors

  • Tumor Origin: Breast, Head & Neck, NSCLC-AC, NSCLC-SQ, Endometrial, Gastroesophageal, Pancreatic, Colorectal, Ovarian, Liver

  • Molecular Profiling: STAR Health Network xT molecular profiles and whole transcriptome
     

• PanTumor IO™: primary and metastatic tumors with allogeneic MHC-matched PBMCs

  • Tumor Origin: Breast, Head & Neck, NSCLC-AC, NSCLC-SQ, Endometrial, Gastroesophageal, Pancreatic, Colorectal, Ovarian, Liver

  • Molecular Profiling: STAR Health Network xT molecular profiles and whole transcriptome, four digit HLA genotyping

  • Designed to screen cell engagers and adoptive cell therapeutics
     

Single cell RNA sequencing
Characterize cell populations of interest with precision–identify and validate complex signatures and identify biomarkers of therapeutic response

Spatial transcriptomics
Uncover spatio-temporal patterns of gene expression in two dimensions to better characterize the relationships between molecular profiles and therapeutic response

PAN-CANCER TUMOR ORGANOIDS

• Breast

• Colon

• Endometrial Adeno

• Gastric

• Head + Neck SCC

• Liver HCC

• NSCLC Adeno

• NSCLC SCC

• Ovarian

• Pancreatic

Our solutions can be broadly applied to preclinical and post-approval strategies

• Target validation

• Indication selection

• Phenotypic (clinical) + Exploratory (MOA) studies

• Exploration of rare patient mutations and alterations

• Combination identification

• Signature development for responder enrichment

• Immune cell activation

• Label expansion plans

Our Differentiators

500+
commercially available biological models

Full Characterization
of tumor organoids with STAR Health Network xT solid tumor comprehensive profiling

Flexible
3D confocal imaging assays with AI analytics on every tumor organoid drug sensitivity screen

Innovative Pipeline
of automation-driven assays enable expedited experimental processes